<DOC>
	<DOCNO>NCT00802126</DOCNO>
	<brief_summary>The purpose study report treatment effect safety combine intravitreal bevacizumab ( IVB ) photodynamic therapy ( PDT ) verteporfin use reduce ( RF ) light fluence rate , choroidal neovascularization ( CNV ) secondary pathologic myopia .</brief_summary>
	<brief_title>Intravitreal Bevacizumab Low Fluence Photodynamic Therapy</brief_title>
	<detailed_description>In retrospective interventional case series , 16 patient myopic CNV include . All patient treat 1.25 mg intravitreal bevacizumab follow RF-PDT ( 25 J/cmÂ² ) , 2 day later . All patient previously treat IVB monotherapy active leaking CNV occur 90 120 day treatment . Best-corrected visual acuity ( BCVA-ETDRS ) , foveal thickness ( FT ) optical coherence tomography ( OCT ) , fluorescein indocyanine green angiographic ( FA ; ICG ) finding record . Follow-up evaluation carry 12 month .</detailed_description>
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Myopic CNV , CNV leakage CNV associate high myopia No activity CNV</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>